Form 10-Q · Quarterly report
Bio-Techne 10-Q, filed Nov 6, 2026
- Filed
- CIK
- 0000842023
- Accession no.
- 0001104659-26-123907
Summary
Bio-Techne's net sales rose 5% to $299.7 million in the quarter ended September 30, 2026, with organic revenue up 7%. Shareholders approved the company's pending acquisition by Merck KGaA, which is expected to close in late 2026 or early 2027 subject to closing conditions.
Key points
- Consolidated gross margin was 65.6%, unchanged year over year, while adjusted gross margin fell to 69.3% from 70.2%.
- Protein Sciences net sales rose 9% to $219.7 million, and Diagnostics and Spatial Biology net sales rose 1% to $80.2 million.
- Selling, general and administrative expenses increased 15% to $133.7 million, and research and development expenses increased 9% to $26.3 million.
- Cash and cash equivalents were $350.0 million as of September 30, 2026, compared with $264.7 million as of June 30, 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT'S DISCUSSION OVERVIEW Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (Bio-Techne, we, our, us or the Company) develop, manufacture and sell biotechnology reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.